First-Line Treatment of Pulmonary Mucormycosis
Pulmonary mucormycosis is a rapidly progressive fungal infection that demands prompt, coordinated intervention. Evidence-based first-line management combines surgical and antifungal strategies from day one.
Treatment Response Goal
The primary target is achieving stable disease or a partial response on imaging, assessed at regular intervals — with imaging recommended as frequently as weekly in patients who are clinically unstable.
First-Line Approach (Overview)
Management begins with early complete surgical intervention alongside immediate systemic antifungal therapy — both initiated from the first day of treatment, without dose escalation over time. Once a response is established, transition to an oral antifungal option is supported.
The full regimen — including agent selection, dosing, sequencing, and step-down criteria — is available in the structured protocol.
References
- The guideline group strongly supports an early complete surgical treatment for mucormycosis whenever possible, in addition to systemic antifungal treatment.
- First-line treatment with liposomal amphotericin B 5 – 10 mg/kg per day is strongly supported across all patterns of organ involvement.
- Doses should not be slowly increased over several days; rather, the full daily dose should be given from the first treatment day.
- When switching to oral treatment, use of isavuconazole or posaconazole delayed release tablets is strongly supported.
- There is moderate support for intravenous treatment until stable disease is achieved.
- In view of the rapid progress of mucormycosis, weekly CT scans are strongly recommended, particularly in unstable patients.
View source ↗